Navigation Links
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Date:10/2/2007

ity when compared to reagents produced through traditional methods.

The SEQer catalog of antibodies addresses a number of well-known challenges associated with currently available reagents. Specifically, deficiencies in the ability to replicate the three dimensional conformation of target proteins through synthetic immunogens have resulted in reagents that do not reliably recognize or differentiate their intended targets. This, in turn, limits reagent performance and creates a level of uncertainty regarding the data produced with traditionally produced reagents. The SEQer antibody is focused on addressing the loss of productivity in research and development endeavors.

"The performance of our SEQer antibodies has been demonstrated with our many private and public collaborators in numerous assays," Mr. Knight said. "The programs have included significantly large screens for oncology markers and the ability to stain disease-associated proteins across thousands of clinical biopsy samples. More targeted studies have shown the ability to differentiate highly conserved proteins in cell sorting assays, the ability to react with traditionally elusive proteins of interest, and be directed through SDI's design algorithms to target functional sites in monoclonal applications."

SDI's GAT-produced antibodies are significantly better than traditional protein/peptide-produced antibodies, as they are produced in vivo by the host animal's natural immune system, and are therefore able to behave both chemically and mechanically as any naturally produced antibody would.

Oncology Focus

The SEQer oncology-focused portfolio is comprised of antibody tools that target proteins associated with cancer pathogenesis and progression, thereby succeeding in delivering usable data for more proteins and in more applications. SDI strategically focused on the area of oncology, as more than half of NIH-funded research and the majority of proteomic efforts are currently focu
'/>"/>

SOURCE Strategic Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
2. New Advances in Gastric Diagnostics: Smaller is Better
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
8. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
9. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
10. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
11. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... AMSTERDAM, December 16 Today, Avantium ... Executive Officer of its pharmaceutical,business. Gunnar Staaf ... and Eli Lilly & Company, in a ... is an important step in Avantium,s plan ... to create a,stand-alone pharmaceutical company based on ...
(Date:12/16/2009)... Senate Vote Against Lower Prescription Drug Prices ... Senate on Tuesday night rejected an amendment to ... would help make prescription drugs more affordable by ... lower priced drugs from abroad. The bipartisan ... Dorgan, Snowe, McCain, Grassley and Stabenow, would have ...
(Date:12/16/2009)... Calif., Dec. 16 Frost & ... Bujnoch, looks forward to speaking at the ... taking place on January 9, 2010 in ... the emerging market of consumer-based digital health ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch ...
Breaking Medicine Technology:Avantium Appoints Gunnar Staaf as CEO Pharma 2AARP Illinois Key Vote News Alert 2Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Optimization and Scale up of a Hydrodynamically Limited Anti Solvent Crystallization Process 3A From Lab to Plant 13541 1Optimization and Scale up of a Hydrodynamically Limited Anti Solvent Crystallization Process 3A From Lab to Plant 13541 2TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 1TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 2TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 3TrueVision Teams with Ophthalmologists to Help Cure World Blindness for Treatable Cataracts Debut of 3D Training Video for Manual Small Incision C 54393 4Medco Health Solutions United Drug Announce U K Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions 3B Innov 54388 1Medco Health Solutions United Drug Announce U K Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions 3B Innov 54388 2Medco Health Solutions United Drug Announce U K Homecare Pharmacy Joint Venture Serving Patients with Chronic and Complex Health Conditions 3B Innov 54388 3
... Product Candidate in Clinical Trials, SEATTLE, Sept. ... enrolling patients in a Phase 1/Phase 2 study ... use during,ophthalmologic surgery. At least 60 patients undergoing ... enrollment in the,study., "With the initiation of ...
... 8 FluoroPharma, Inc. announced today that,Dr. ... Advisor,will report on two preclinical studies demonstrating ... molecular imaging agents for detection,of Alzheimer,s disease ... Molecular,Imaging Congress, in Nice, France on September ...
Other Medicine Technology:Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 2FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents 3
(Date:12/16/2009)... 16, 2009 -- Every year in the United States, ... patients die of the disease, making it the second ... lung cancer. , As researchers and clinicians fervently look ... generating thousands of studies producing more and more promising ... cancer and genetics at Case Western Reserve University School ...
(Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
(Date:12/16/2009)... most widely used human embryonic stem cell lines lack ... that must be addressed to ensure that all sectors ... a University of Michigan research team. ,, In the ... analyzed 47 embryonic stem cell lines, including most of ... scientists determined the genetic ancestry of each line and ...
(Date:12/16/2009)... long-term goal, researchers say , , WEDNESDAY, Dec. 16 ... predict whether a patient will suffer a second stroke ... is an important new tool because studies have shown ... a first stroke are more likely to die or ... Hospital and Harvard Medical School, said in an American ...
(Date:12/16/2009)... Wellcome Trust Sanger Institute announce the first comprehensive analyses ... by mutations in the DNA of cancer cells which ... a malignant melanoma and a lung cancer, reveal for ... genomes of two cancers. , Lung cancer causes around ... associated with smoking. The number of mutations found suggest ...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6
... with a second newer agent has proven to be effective ... be published in its July 7th special HIV/AIDS issue. ... 18 nations and more than 30 centers in the United ... resistant HIV the potential of receiving two investigational new drugs ...
... police inquiries as focus shifted to Australia. ... attacks in UK raided two hospitals in Western Australia and ... Indian. ,However, WA Premier Alan Carpenter said he ... ,"There is nothing that has been presented to ...
... a blood-clotting protein found in circulating blood, has been ... neuronal cells , a process that is necessary for ... ,The findings by researchers at the University ... explain why the human body is unable to repair ...
... Didrick of Naples, Florida, has come up with a fascinating ... in 150 persons do lose a digit , it is ... because it has no batteries, electronics, servos or actuators. Instead, ... the surviving part of the wearer's finger, curls a set ...
... a way to produce blood vessels by engineering tissues ... ,Researchers at the University at Buffalo Department of Chemical ... an excellent source of adult stem cells, containing smooth ... cells can be used in regenerative medicine for cardiovascular ...
... conducted by Henley Management College and the University of Milan ... age of 65 is significantly higher than it is ... study was to make the first step in the modelling ... prescribing funds. ,The research found that the mean ...
Other Medicine News:Health News:New Drugs Show Promise in Fighting Drug-Resistant HIV 2Health News:New Drugs Show Promise in Fighting Drug-Resistant HIV 3Health News:More Indian Doctors Questioned in Australia as UK Terror Plot Inquiry Widens 2Health News:Fibrinogen may Inhibit Spinal Cord Regeneration 2Health News:A Mechanical Prosthetic Close to the Real Thing 2Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2
... The Volk G-1 trabeculum provides the highest magnification ... for viewing and treating the trabecular meshwork. ... the anterior chamber angle while the central portion ... the posterior pole for signs of glaucoma and ...
... Volks Disposable SSV® Vitrectomy Lenses are a ... to enable a view of a particular region ... contact lens element weighs less than 1 gram ... with the typical shape of a human cornea. ...
... 30° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... The 30° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: